Resultado de búsqueda
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
June 10 2024 Statement: Zantac (ranitidine) litigation – Kasza case. June 07 2024 US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk. View all press releases.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London.
GSKpro es exclusivamente para los profesionales de la salud, en donde les brindamos información, servicios y asistencia relacionada a los productos de GSK.
Find the latest GSK plc (GSK) stock quote, history, news and other vital information to help you with your stock trading and investing.
GSK | 4,006,762 followers on LinkedIn. We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia.
At a glance. GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
GSK 2929 Walnut Street Ste. 1700 Philadelphia, PA 19104 United States. North Carolina: GSK 410 Blackwell St. Durham, NC 27701 United States How can we help you? Visit our GSK Help Centre for patients, caregivers and HCPs in US. Alternatively, call us on Tel: +1 888 825 5249. Monday, Tuesday, Thursday, Friday: 08:30 AM - 5:30 PM ET. Wednesday: 8 ...
3 de jun. de 2024 · GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab-gxly) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.
